Abstract
Summary
Fibromyalgia syndrome (FS) is a non-articular rheumatic disorder characterized by pain and stiffness of the musculoskeletal system and tenderness in specific sites.Fibromyalgia syndrome can be secondary to trauma, a variety of rheumatic diseases, such as osteoarthritis, rheumatoid arthritis and a variety of non-rheumatic diseases (such as hypothyroidism, malignant tumors).
The global market for Fibromyalgia Treatment was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Fibromyalgia Treatment, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Fibromyalgia Treatment by region & country, by Type, and by Application.
The Fibromyalgia Treatment market size, estimations, and forecasts are provided in terms of sales volume (KG) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Fibromyalgia Treatment.
Market Segmentation
By Company
Eli Lilly and Company
Pfizer
Novartis AG
Allergan
Aptinyx
Prismic Pharmaceuticals
Innovative Med Concepts
Intec Pharma Ltd.
Astellas Pharma
Savella
Sun Pharmaceutical Industries
Mylan NV
Teva Pharmaceutical Industries
Daiichi Sankyo
Forest Pharmaceuticals
Meiji Seika Pharma
Tonix Pharmaceuticals
Theravance Biopharma
Segment by Type:
Antidepressants
Anticonvulsants
Muscle Relaxants
Narcotic Analgesics
Non-narcotic Analgesics
Segment by Application
Hospitals Pharmacies
Clinic Pharmacy
Retail Drug Stores
Online Pharmacies
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Fibromyalgia Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Fibromyalgia Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Fibromyalgia Treatment in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
The global market for Fibromyalgia Treatment was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Fibromyalgia Treatment, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Fibromyalgia Treatment by region & country, by Type, and by Application.
The Fibromyalgia Treatment market size, estimations, and forecasts are provided in terms of sales volume (KG) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Fibromyalgia Treatment.
Market Segmentation
By Company
Eli Lilly and Company
Pfizer
Novartis AG
Allergan
Aptinyx
Prismic Pharmaceuticals
Innovative Med Concepts
Intec Pharma Ltd.
Astellas Pharma
Savella
Sun Pharmaceutical Industries
Mylan NV
Teva Pharmaceutical Industries
Daiichi Sankyo
Forest Pharmaceuticals
Meiji Seika Pharma
Tonix Pharmaceuticals
Theravance Biopharma
Segment by Type:
Antidepressants
Anticonvulsants
Muscle Relaxants
Narcotic Analgesics
Non-narcotic Analgesics
Segment by Application
Hospitals Pharmacies
Clinic Pharmacy
Retail Drug Stores
Online Pharmacies
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Fibromyalgia Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Fibromyalgia Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Fibromyalgia Treatment in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
1.1 Fibromyalgia Treatment Product Introduction
1.2 Global Fibromyalgia Treatment Market Size Forecast
1.2.1 Global Fibromyalgia Treatment Sales Value (2019-2030)
1.2.2 Global Fibromyalgia Treatment Sales Volume (2019-2030)
1.2.3 Global Fibromyalgia Treatment Sales Price (2019-2030)
1.3 Fibromyalgia Treatment Market Trends & Drivers
1.3.1 Fibromyalgia Treatment Industry Trends
1.3.2 Fibromyalgia Treatment Market Drivers & Opportunity
1.3.3 Fibromyalgia Treatment Market Challenges
1.3.4 Fibromyalgia Treatment Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Fibromyalgia Treatment Players Revenue Ranking (2023)
2.2 Global Fibromyalgia Treatment Revenue by Company (2019-2024)
2.3 Global Fibromyalgia Treatment Players Sales Volume Ranking (2023)
2.4 Global Fibromyalgia Treatment Sales Volume by Company Players (2019-2024)
2.5 Global Fibromyalgia Treatment Average Price by Company (2019-2024)
2.6 Key Manufacturers Fibromyalgia Treatment Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Fibromyalgia Treatment Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Fibromyalgia Treatment
2.9 Fibromyalgia Treatment Market Competitive Analysis
2.9.1 Fibromyalgia Treatment Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Fibromyalgia Treatment Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Fibromyalgia Treatment as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Antidepressants
3.1.2 Anticonvulsants
3.1.3 Muscle Relaxants
3.1.4 Narcotic Analgesics
3.1.5 Non-narcotic Analgesics
3.2 Global Fibromyalgia Treatment Sales Value by Type
3.2.1 Global Fibromyalgia Treatment Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Fibromyalgia Treatment Sales Value, by Type (2019-2030)
3.2.3 Global Fibromyalgia Treatment Sales Value, by Type (%) (2019-2030)
3.3 Global Fibromyalgia Treatment Sales Volume by Type
3.3.1 Global Fibromyalgia Treatment Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Fibromyalgia Treatment Sales Volume, by Type (2019-2030)
3.3.3 Global Fibromyalgia Treatment Sales Volume, by Type (%) (2019-2030)
3.4 Global Fibromyalgia Treatment Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospitals Pharmacies
4.1.2 Clinic Pharmacy
4.1.3 Retail Drug Stores
4.1.4 Online Pharmacies
4.2 Global Fibromyalgia Treatment Sales Value by Application
4.2.1 Global Fibromyalgia Treatment Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Fibromyalgia Treatment Sales Value, by Application (2019-2030)
4.2.3 Global Fibromyalgia Treatment Sales Value, by Application (%) (2019-2030)
4.3 Global Fibromyalgia Treatment Sales Volume by Application
4.3.1 Global Fibromyalgia Treatment Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Fibromyalgia Treatment Sales Volume, by Application (2019-2030)
4.3.3 Global Fibromyalgia Treatment Sales Volume, by Application (%) (2019-2030)
4.4 Global Fibromyalgia Treatment Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Fibromyalgia Treatment Sales Value by Region
5.1.1 Global Fibromyalgia Treatment Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Fibromyalgia Treatment Sales Value by Region (2019-2024)
5.1.3 Global Fibromyalgia Treatment Sales Value by Region (2025-2030)
5.1.4 Global Fibromyalgia Treatment Sales Value by Region (%), (2019-2030)
5.2 Global Fibromyalgia Treatment Sales Volume by Region
5.2.1 Global Fibromyalgia Treatment Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Fibromyalgia Treatment Sales Volume by Region (2019-2024)
5.2.3 Global Fibromyalgia Treatment Sales Volume by Region (2025-2030)
5.2.4 Global Fibromyalgia Treatment Sales Volume by Region (%), (2019-2030)
5.3 Global Fibromyalgia Treatment Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Fibromyalgia Treatment Sales Value, 2019-2030
5.4.2 North America Fibromyalgia Treatment Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Fibromyalgia Treatment Sales Value, 2019-2030
5.5.2 Europe Fibromyalgia Treatment Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Fibromyalgia Treatment Sales Value, 2019-2030
5.6.2 Asia Pacific Fibromyalgia Treatment Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Fibromyalgia Treatment Sales Value, 2019-2030
5.7.2 South America Fibromyalgia Treatment Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Fibromyalgia Treatment Sales Value, 2019-2030
5.8.2 Middle East & Africa Fibromyalgia Treatment Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Fibromyalgia Treatment Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Fibromyalgia Treatment Sales Value
6.2.1 Key Countries/Regions Fibromyalgia Treatment Sales Value, 2019-2030
6.2.2 Key Countries/Regions Fibromyalgia Treatment Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Fibromyalgia Treatment Sales Value, 2019-2030
6.3.2 United States Fibromyalgia Treatment Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Fibromyalgia Treatment Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Fibromyalgia Treatment Sales Value, 2019-2030
6.4.2 Europe Fibromyalgia Treatment Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Fibromyalgia Treatment Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Fibromyalgia Treatment Sales Value, 2019-2030
6.5.2 China Fibromyalgia Treatment Sales Value by Type (%), 2023 VS 2030
6.5.3 China Fibromyalgia Treatment Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Fibromyalgia Treatment Sales Value, 2019-2030
6.6.2 Japan Fibromyalgia Treatment Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Fibromyalgia Treatment Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Fibromyalgia Treatment Sales Value, 2019-2030
6.7.2 South Korea Fibromyalgia Treatment Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Fibromyalgia Treatment Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Fibromyalgia Treatment Sales Value, 2019-2030
6.8.2 Southeast Asia Fibromyalgia Treatment Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Fibromyalgia Treatment Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Fibromyalgia Treatment Sales Value, 2019-2030
6.9.2 India Fibromyalgia Treatment Sales Value by Type (%), 2023 VS 2030
6.9.3 India Fibromyalgia Treatment Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Eli Lilly and Company
7.1.1 Eli Lilly and Company Company Information
7.1.2 Eli Lilly and Company Introduction and Business Overview
7.1.3 Eli Lilly and Company Fibromyalgia Treatment Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Eli Lilly and Company Fibromyalgia Treatment Product Offerings
7.1.5 Eli Lilly and Company Recent Development
7.2 Pfizer
7.2.1 Pfizer Company Information
7.2.2 Pfizer Introduction and Business Overview
7.2.3 Pfizer Fibromyalgia Treatment Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Pfizer Fibromyalgia Treatment Product Offerings
7.2.5 Pfizer Recent Development
7.3 Novartis AG
7.3.1 Novartis AG Company Information
7.3.2 Novartis AG Introduction and Business Overview
7.3.3 Novartis AG Fibromyalgia Treatment Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Novartis AG Fibromyalgia Treatment Product Offerings
7.3.5 Novartis AG Recent Development
7.4 Allergan
7.4.1 Allergan Company Information
7.4.2 Allergan Introduction and Business Overview
7.4.3 Allergan Fibromyalgia Treatment Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Allergan Fibromyalgia Treatment Product Offerings
7.4.5 Allergan Recent Development
7.5 Aptinyx
7.5.1 Aptinyx Company Information
7.5.2 Aptinyx Introduction and Business Overview
7.5.3 Aptinyx Fibromyalgia Treatment Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Aptinyx Fibromyalgia Treatment Product Offerings
7.5.5 Aptinyx Recent Development
7.6 Prismic Pharmaceuticals
7.6.1 Prismic Pharmaceuticals Company Information
7.6.2 Prismic Pharmaceuticals Introduction and Business Overview
7.6.3 Prismic Pharmaceuticals Fibromyalgia Treatment Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Prismic Pharmaceuticals Fibromyalgia Treatment Product Offerings
7.6.5 Prismic Pharmaceuticals Recent Development
7.7 Innovative Med Concepts
7.7.1 Innovative Med Concepts Company Information
7.7.2 Innovative Med Concepts Introduction and Business Overview
7.7.3 Innovative Med Concepts Fibromyalgia Treatment Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Innovative Med Concepts Fibromyalgia Treatment Product Offerings
7.7.5 Innovative Med Concepts Recent Development
7.8 Intec Pharma Ltd.
7.8.1 Intec Pharma Ltd. Company Information
7.8.2 Intec Pharma Ltd. Introduction and Business Overview
7.8.3 Intec Pharma Ltd. Fibromyalgia Treatment Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Intec Pharma Ltd. Fibromyalgia Treatment Product Offerings
7.8.5 Intec Pharma Ltd. Recent Development
7.9 Astellas Pharma
7.9.1 Astellas Pharma Company Information
7.9.2 Astellas Pharma Introduction and Business Overview
7.9.3 Astellas Pharma Fibromyalgia Treatment Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Astellas Pharma Fibromyalgia Treatment Product Offerings
7.9.5 Astellas Pharma Recent Development
7.10 Savella
7.10.1 Savella Company Information
7.10.2 Savella Introduction and Business Overview
7.10.3 Savella Fibromyalgia Treatment Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Savella Fibromyalgia Treatment Product Offerings
7.10.5 Savella Recent Development
7.11 Sun Pharmaceutical Industries
7.11.1 Sun Pharmaceutical Industries Company Information
7.11.2 Sun Pharmaceutical Industries Introduction and Business Overview
7.11.3 Sun Pharmaceutical Industries Fibromyalgia Treatment Sales, Revenue and Gross Margin (2019-2024)
7.11.4 Sun Pharmaceutical Industries Fibromyalgia Treatment Product Offerings
7.11.5 Sun Pharmaceutical Industries Recent Development
7.12 Mylan NV
7.12.1 Mylan NV Company Information
7.12.2 Mylan NV Introduction and Business Overview
7.12.3 Mylan NV Fibromyalgia Treatment Sales, Revenue and Gross Margin (2019-2024)
7.12.4 Mylan NV Fibromyalgia Treatment Product Offerings
7.12.5 Mylan NV Recent Development
7.13 Teva Pharmaceutical Industries
7.13.1 Teva Pharmaceutical Industries Company Information
7.13.2 Teva Pharmaceutical Industries Introduction and Business Overview
7.13.3 Teva Pharmaceutical Industries Fibromyalgia Treatment Sales, Revenue and Gross Margin (2019-2024)
7.13.4 Teva Pharmaceutical Industries Fibromyalgia Treatment Product Offerings
7.13.5 Teva Pharmaceutical Industries Recent Development
7.14 Daiichi Sankyo
7.14.1 Daiichi Sankyo Company Information
7.14.2 Daiichi Sankyo Introduction and Business Overview
7.14.3 Daiichi Sankyo Fibromyalgia Treatment Sales, Revenue and Gross Margin (2019-2024)
7.14.4 Daiichi Sankyo Fibromyalgia Treatment Product Offerings
7.14.5 Daiichi Sankyo Recent Development
7.15 Forest Pharmaceuticals
7.15.1 Forest Pharmaceuticals Company Information
7.15.2 Forest Pharmaceuticals Introduction and Business Overview
7.15.3 Forest Pharmaceuticals Fibromyalgia Treatment Sales, Revenue and Gross Margin (2019-2024)
7.15.4 Forest Pharmaceuticals Fibromyalgia Treatment Product Offerings
7.15.5 Forest Pharmaceuticals Recent Development
7.16 Meiji Seika Pharma
7.16.1 Meiji Seika Pharma Company Information
7.16.2 Meiji Seika Pharma Introduction and Business Overview
7.16.3 Meiji Seika Pharma Fibromyalgia Treatment Sales, Revenue and Gross Margin (2019-2024)
7.16.4 Meiji Seika Pharma Fibromyalgia Treatment Product Offerings
7.16.5 Meiji Seika Pharma Recent Development
7.17 Tonix Pharmaceuticals
7.17.1 Tonix Pharmaceuticals Company Information
7.17.2 Tonix Pharmaceuticals Introduction and Business Overview
7.17.3 Tonix Pharmaceuticals Fibromyalgia Treatment Sales, Revenue and Gross Margin (2019-2024)
7.17.4 Tonix Pharmaceuticals Fibromyalgia Treatment Product Offerings
7.17.5 Tonix Pharmaceuticals Recent Development
7.18 Theravance Biopharma
7.18.1 Theravance Biopharma Company Information
7.18.2 Theravance Biopharma Introduction and Business Overview
7.18.3 Theravance Biopharma Fibromyalgia Treatment Sales, Revenue and Gross Margin (2019-2024)
7.18.4 Theravance Biopharma Fibromyalgia Treatment Product Offerings
7.18.5 Theravance Biopharma Recent Development
8 Industry Chain Analysis
8.1 Fibromyalgia Treatment Industrial Chain
8.2 Fibromyalgia Treatment Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Fibromyalgia Treatment Sales Model
8.5.2 Sales Channel
8.5.3 Fibromyalgia Treatment Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer